3F公司推出无需缝合的心脏瓣膜

一种新型主动脉心脏瓣膜的设计，使得外科医生将瓣膜植入主动脉环后无需进行缝合。从而将心肺分流的时间节约了30分钟甚至更多。

波兰Jagiellonian大学(Krakow, Poland)的一个外科小组，最近不使用缝线，对一例76岁患者的失去功能的主动脉瓣进行了置换。根据第一例手术的成功经验，该小组已经对符合标准的患者置换了另外2个瓣膜。所有瓣膜植入时间都少于1分钟，大大减少了主动脉钳夹以及心肺分流时间。所有瓣膜工作良好。这种瓣膜叫做3F Enable主动脉心脏瓣膜，是3F集团公司(Lake Forest, CA, USA)研制开发的。

Jagiellonion大学心血管外科和移植科主任Jerzy Sadowski医生解释说：“在全球范围内象我们这样的大型手术中心，绝大多数瓣膜置换病人在接受心脏瓣膜置换手术的同时，还要进行冠状动脉分流移植手术。单次或者多次血管移植是十分耗时的工作。在单个病例中联合进行这两项手术是本项研究的主要目标。标准机械或者组织瓣膜需要我花30分钟来缝合。而这种新型3F产品使得我在不到50秒的时间内达到相同的目标。

这种受保护的3F工艺技术是以管状瓣膜概念为基础的产品，使其成为创伤性较小的手术，可以用于主动脉瓣和二尖瓣置换手术。

Sutureless Replacement Heart Valve
 
A new aortic heart valve is designed to eliminate the need for a surgeon to suture the device into the aortic annulus of the patient, saving around 30 minutes or more of cardiopulmonary bypass time.

Using no stitches, a surgical team at Jagiellonian University (Krakow, Poland) recently replaced the failing aortic heart valve of a 76-year-old patient. Based on the success of the first implant, the team implanted two additional valves in patients meeting the selection criteria. All valves required less than one minute of implantation positioning time, with dramatic reduction of aorta cross-clamp time and cardiopulmonary bypass time. All valves were fully competent. Called the 3F Enable aortic heart valve, the new valve was developed by 3F Therapeutics, Inc. (Lake Forest, CA, USA).

“In major surgical centers like ours around the world, most of these valve replacement patients also have coronary artery bypass graft surgery at the same time their heart valves are replaced,” explained Dr. Jerzy Sadowski, M.D., Ph.D., chief of the department of cardiovascular surgery and transplantology at Jagiellonion University. “Single or multiple vessel grafting is also time consuming, and the combination of these operations into a single case is the larger target of this research endeavor. A standard mechanical or tissue heart valve takes me about 30 minutes to suture in place. This new 3F product allowed me to achieve the same result in less than 50 seconds.”

The patented technologies of 3F Therapeutics, based on a tubular valve concept, lend themselves to minimally invasive surgery and will be applicable to both aortic and mitral valve replacement.